Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Subscribe To Our Newsletter & Stay Updated